Relyvrio: ALS drug gains FDA approval despite uncertainty about efficacy

CNN – A new treatment for amyotrophic lateral sclerosis, or ALS, has been approved by the U.S. Food and Drug Administration. On Thursday, the FDA announced the approval of Relyvrio, developed by Amylyx Pharmaceuticals. The oral drug can be taken as a standalone therapy or with other treatments, according to the company, and has been … Read more

Prime Medicine spells out IPO plans for “word processor” or gene editing

Gene editing research is looking for more precise approaches, with the goal of avoiding off-target changes that cause problems in other parts of the genome. Prime Medicine aims to offer that precision along with the potential to address a wider range of genetic diseases. Biotechnology has yet to test this technology on patients, but it … Read more

Rejuvenate Bio CEO Highlights Ambitious Approach of Using Gene Therapy to Reverse Aging

Rejuvenate Bio is a gene therapy startup looking to reverse aging. In response to emailed questions, CEO and co-founder Daniel Oliver talked about how he and his co-founder started the company and their vision for treatment. age-related conditions. Why did you start this company? The idea was born in George Church’s laboratory at Harvard Medical … Read more

Transparency of laboratory testing will improve patient care and reduce costs

The need for understandable and transparent pricing for medical services in the United States has increased urgently with the continued rise in out-of-pocket healthcare costs. Americans are delaying health care because they are unsure of the cost or cannot afford it. A recent Willis Tower Watson (WTW) survey of 9,600 U.S. workers showed that 4 … Read more

Exact sciences: don’t hold him guilty by association

Wrong place, wrong time. This may be the most concise explanation for Exact Sciences’ incredible one-year performance (ES) buffer stock. Shares of the genetic testing company have fallen 65% over the past year, including a 54% decline since the start of 2022. Investors shouldn’t be surprised to see Exact Sciences issue a small valuation during … Read more

Omicron-targeted COVID boosters are expected this week, but experts fear there may be low absorption

The Food and Drug Administration is expected to clear new COVID-19 booster injections this week that target the latest versions of the omicron variant, but will do so without data from a study that will prove the injections were safe and worked in humans. Dose clearance, with no human test data known as clinical trials, … Read more

Omicron-targeted COVID boosters are expected this week, but experts fear there may be low absorption

The Food and Drug Administration is expected to clear new COVID-19 booster injections this week that target the latest versions of the omicron variant, but will do so without data from a study that will prove the injections were safe and worked in humans. Dose clearance, with no human test data known as clinical trials, … Read more

Pfizer and BioNTech say data shows COVID vaccine is more than 70% effective in young children, with cases on the rise in just 7 states

On Tuesday Pfizer and German partner BioNTech offered up-to-date data on the COVID vaccine to support efficacy in children aged 6 months to 4 years. PFE companies, -2.18% BNTX, -0.04% said updated analysis from 34 cases occurring at least seven days after a three-dose regimen showed vaccine efficacy of 73.2% among children in that age … Read more

Opinion: Now that the S&P 500 looks overbought, see what happens to this downtrend line that defines the bear market

The S&P 500 index extended its gains, as we expected after last week’s breakout on the resistance at 4170. The target was the declining 200-day moving average, which is currently at around 4325. The S&P SPX has “touched” that 200-day MA this week. Furthermore, the downtrend line that defines this bear market (blue line in … Read more

Pharmaceutical stocks are down as investors brace for litigation allegations

The shares of GlaxoSmithKline, Sanofi and Haleon all sold sharply this week, losing tens of billions of market value amid investor fears over potential US legal charges centered on the popular heartburn drug Zantac. This has been a known issue in the background for years, but investor concern erupted this week ahead of the first … Read more